Healx Logo

menu menu
Contact
Patient Groups
  • Rare Treatment Accelerator
    • Partnerships
    Pipeline
    Technology
  • Publications
    • About
  • Careers
  • Board of directors
  • Advisory board
    • Updates
  • News
  • Healx in the media
  • Blog

    • Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void?

    5 March 2019   |  
    X minutes
    Share this story
    Healx on Facebook Healx on Twitter

    You might also like:

    News & Opinion
    Healx Appoints Christopher Moertel as Global Head of Clinical Development
    hello@douglassdigital.com
    News & Opinion
    Healx Announces First Patient Dosed in Phase 2 Trial Evaluating HLX-1502 for the Treatment of Neurofibromatosis Type 1
    hello@douglassdigital.com
    In the media
    Tim Guilliams talks about Using AI to De-Risk Rare Disease Drug Development
    hello@douglassdigital.com

    © Healx. All rights reserved.

    Company registration: 09018507. VAT number GB212364641.